Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hims & Hers Health, Inc. Class A Common Stock
(NY:
HIMS
)
43.58
-1.19 (-2.66%)
Official Closing Price
Updated: 7:00 PM EST, Feb 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Hims & Hers Health, Inc. Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
February 10, 2025
Via
The Motley Fool
Hims & Hers Health Unusual Options Activity For February 10
February 10, 2025
Via
Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
February 10, 2025
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads.
Via
Benzinga
Hims & Hers Health Unusual Options Activity
February 07, 2025
Via
Benzinga
Hims & Hers Health Unusual Options Activity For February 03
February 03, 2025
Via
Benzinga
Unlocking the Growth Potential of NYSE:HIMS.
January 31, 2025
A fundamental analysis of (NYSE:HIMS): Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing?
Via
Chartmill
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
February 10, 2025
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system.
Via
Stocktwits
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst
February 10, 2025
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.
Via
Benzinga
Topics
World Trade
Exposures
Tariff
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
February 07, 2025
Shares rocketed on Friday, but the company might not be out of hot water yet.
Via
Investor's Business Daily
EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year's NFL Championship
February 07, 2025
Benzinga readers pick whether a $7 million Super Bowl cost is worth it for companies and how likely they are to look up a company that may be new to them after the big game.
Via
Benzinga
Is Hims & Hers Health Stock a Buy?
January 28, 2025
Here's a look into one of healthcare's hottest growth stocks.
Via
The Motley Fool
Hims & Hers Health Unusual Options Activity
January 21, 2025
Via
Benzinga
Why the high growth investor may take a look at NYSE:HIMS.
January 20, 2025
Unlocking the high Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS).
Via
Chartmill
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
February 07, 2025
A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
February 07, 2025
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...
Via
Stocktwits
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
February 02, 2025
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners...
Via
Benzinga
Is Hims & Hers Stock in Trouble?
January 16, 2025
Via
The Motley Fool
Evaluating NYSE:HIMS for Growth Investment Opportunities.
January 10, 2025
Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing?
Via
Chartmill
What 12 Analyst Ratings Have To Say About Hims & Hers Health
January 06, 2025
Via
Benzinga
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
January 22, 2025
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions
Via
MarketBeat
8 Health Care Stocks Whale Activity In Today's Session
January 20, 2025
Via
Benzinga
Hims & Hers Health: A Stock to Trade or Own?
January 20, 2025
HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.
Via
MarketBeat
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
January 17, 2025
Via
The Motley Fool
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
January 17, 2025
Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025
Via
MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
January 14, 2025
Via
Benzinga
Hims & Hers Stock Is Poised for a Major Surge in 2025
January 10, 2025
The focus is on GLP-1s, but there's more to Hims & Hers than one product.
Via
The Motley Fool
What's Going On With Hims & Hers Health Stock?
January 09, 2025
Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations.
Via
Benzinga
Stock Picks 2024 Year In Review
January 01, 2025
Unlike 2023, 2024 was a very concentrated year, with just a few key large-cap stocks driving much of the index's returns.
Via
Talk Markets
Topics
Stocks / Equities
Is Hims & Hers Health a Millionaire Maker?
January 01, 2025
Arguments are piling up for why the company might fail, but the business continues to deliver strong results.
Via
The Motley Fool
3 Hot Stocks That Can Double Again in 2025
December 31, 2024
Three unlikely winners of 2024 can lead the way in the year ahead.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.